Pilot phase identifies variants of interest in 30% of participants; pharmacogenomics in 100%
Phoenix, AZ — HudsonAlpha Institute for Biotechnology announced today at the annual ACMG meeting the Insight Genome for people interested in unlocking the secrets of their genome, or genetic code. Insight Genome offers clinical whole genome sequencing and pharmacogenomic testing for current and future healthcare planning.
David Bick, MD, faculty investigator at HudsonAlpha and clinical geneticist at Smith Family Clinic for Genomic Medicine, presented early findings from a pilot group of adults who participated in Insight Genome today at the ACMG meeting.
Seven out of 24 patients were found to have a variant that may relate to their phenotype (condition/symptoms).
“This information is meaningful. By identifying variants linked to phenotype or variants that may be significant, we can provide answers to some of the questions they have been asking. These patients also now know the diseases that they are not carrying, which can provide a measure of comfort in some cases,” said Bick.
The pharmacogenomic panel that accompanies the whole genome sequencing, yielded information about at least one drug in 100% of participants. Three or more drugs were affected in 50% of those patients.
“Taking the right medication at the right dose is critically important for patients, yet this is a test that isn’t yet regularly offered. We think it’s time to change that paradigm,” added Bick.
“Insight Genome was developed specifically to tell patients today about their risks for developing specific medical conditions– or passing them onto their children– and to help inform future healthcare decisions,” said Howard Jacob, PhD, HudsonAlpha executive vice president for genomic medicine.
“Whole genome sequencing offers information not found in one comprehensive tool elsewhere,” continued Jacob. “Many people have heard us talk about rare, undiagnosed disease and how do we apply this technology, but the holy grail is how do we deploy this for everybody?” said Jacob.
Insight Genome is comprised of two elements, all based on your personal genome:
- A clinical report. This is medical information you and your physician can use.
- Pharmacogenomic report from Kailos Genetics (pharmacogenomics are how your genes impact your response to medications).
The initial clinical site for Insight Genome is to Smith Family Clinic for Genomic Medicine on the HudsonAlpha campus in Huntsville, Ala. You must be 19 years of age or older.
Information is available at the HudsonAlpha Clinical Services Lab booth #323 at ACMG. Or visit www.smithfamilyclinic.org/insightgenome.
About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological challenges. Opened in 2008, its mission is four-fold: sparking scientific discoveries that can impact human health and well-being; bringing genomic medicine into clinical care; fostering life sciences entrepreneurship and business growth; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus encourage collaborations that produce advances in medicine and agriculture. Under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education, and includes more than 30 diverse biotech companies on campus. To learn more about HudsonAlpha, visit: http://hudsonalpha.org/.